Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity

Dr. Keith Vossel, Professor of Neurology and Director of the UCLA Easton Center, published the highly anticipated results of a phase 2a randomized, placebo-controlled clinical trial of the anti-seizure medication levetiracetam for Alzheimer’s disease. This study was published in JAMA Neurology. The clinical trial showed that levetiracetam improves cognitive functions in Alzheimer’s patients with epileptic activity. The publication was featured in UCLA Health News and other news resources such as Newswise, Science Daily, News Medical, and more.